Craneware has lowered its revenue expectations for the current year, blaming the lingering fallout from a cyber attack rather than the trading pain caused by upheaval in a key US drug pricing scheme.
The group, which sells software that helps American hospitals manage their finances, said it was taking a prudent view and resetting FY27 revenue to about $185 million, the level of its annual recurring income.
The caution stems from a hacking incident uncovered on 20 July, shortly after the year-end.
Craneware said the immediate impact had been contained, with no disruption to customers or core operations, and an independent investigation had confirmed its systems were secure.
Even so, the full financial cost remains unclear, including any hit to future customer engagement.
The reset overshadowed a solid set of full-year figures, which showed the business holding firm despite separate headwinds from the 340B scheme, a federal programme that lets certain US hospitals buy medicines at a discount.
Revenue for the year to 30 June edged up to $206 million, effectively flat on the prior year.
Profit before tax rose 7% to $25.8 million, while adjusted earnings crept higher and cash generation stayed strong, converting 98% of adjusted core profit into cash.
The company held its total dividend at 32 pence a share.
One warning sign was net revenue retention, a measure of how much existing customers spend year on year, which slipped to 100% from 107% as expansion sales cooled.
To steady the ship, Craneware has launched a review of its cost base aimed at protecting margins over the medium term.
Chief executive Keith Neilson conceded FY26 had been challenging and growth had fallen short.
He argued that easing 340B conditions should lift demand for the group's newer software through the second half of the new financial year, setting up a return to growth the following year.
